Furthermore, the treatment of HCC-1954 cells with a STAT3 inhibitor alone significantly decreased short-term and long-term cancer cell survival, indicating that these cells may benefit from single-agent treatment with STAT3 inhibitors (Figure 5). This evidence concerns the gene STAT3 and hepatocellular carcinoma.